Author Archives: Katherine Poinsatte

SMA treatment benefits increase after Spinraza-Zolgensma switch

Some 70% of children with spinal muscle atrophy (SMA) type 1 who underwent treatment with Spinraza alone or with Spinraza and then Zolgensma reached some motor milestones over 18 months, with greater improvements in those who received Spinraza…

Accurate genetic testing ‘crucial’ for early diagnosis of SMA: Report

The use of advanced genetic testing techniques helped clinicians in China to identify novel mutations in the SMN1 gene in two unrelated children — and thus correctly diagnose them…

Zolgensma found most effective in presymptomatic infants with SMA

Infants with spinal muscular atrophy (SMA) who are presymptomatic and given the gene therapy Zolgensma in the first six weeks of life have better motor, respiratory, and nutritional outcomes, according to a recent study from Europe.